JP2021513355A5 - - Google Patents
Info
- Publication number
- JP2021513355A5 JP2021513355A5 JP2020543344A JP2020543344A JP2021513355A5 JP 2021513355 A5 JP2021513355 A5 JP 2021513355A5 JP 2020543344 A JP2020543344 A JP 2020543344A JP 2020543344 A JP2020543344 A JP 2020543344A JP 2021513355 A5 JP2021513355 A5 JP 2021513355A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cedna vector
- vector according
- nucleotide sequence
- item
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024141968A JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630676P | 2018-02-14 | 2018-02-14 | |
| US201862630670P | 2018-02-14 | 2018-02-14 | |
| US62/630,676 | 2018-02-14 | ||
| US62/630,670 | 2018-02-14 | ||
| US201862680087P | 2018-06-04 | 2018-06-04 | |
| US201862680092P | 2018-06-04 | 2018-06-04 | |
| US62/680,087 | 2018-06-04 | ||
| US62/680,092 | 2018-06-04 | ||
| PCT/US2019/018016 WO2019161059A1 (en) | 2018-02-14 | 2019-02-14 | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024141968A Division JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513355A JP2021513355A (ja) | 2021-05-27 |
| JP2021513355A5 true JP2021513355A5 (https=) | 2022-02-22 |
| JPWO2019161059A5 JPWO2019161059A5 (https=) | 2022-02-22 |
Family
ID=67619630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543344A Pending JP2021513355A (ja) | 2018-02-14 | 2019-02-14 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
| JP2024141968A Pending JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024141968A Pending JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220042035A1 (https=) |
| EP (1) | EP3752191A4 (https=) |
| JP (2) | JP2021513355A (https=) |
| KR (1) | KR20200120649A (https=) |
| CN (1) | CN111818942A (https=) |
| AU (1) | AU2019221642A1 (https=) |
| BR (1) | BR112020016288A2 (https=) |
| CA (1) | CA3091250A1 (https=) |
| IL (1) | IL276469A (https=) |
| MA (1) | MA51842A (https=) |
| MX (1) | MX2020008470A (https=) |
| PH (1) | PH12020551039A1 (https=) |
| SG (1) | SG11202006431WA (https=) |
| WO (1) | WO2019161059A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202545984A (zh) | 2017-08-09 | 2025-12-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| SG11202005271TA (en) * | 2018-01-19 | 2020-07-29 | Generation Bio Co | Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| JP7700101B2 (ja) * | 2019-09-06 | 2025-06-30 | ジェネレーション バイオ カンパニー | 閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 |
| WO2021169167A1 (en) * | 2020-02-29 | 2021-09-02 | Nanjing GenScript Biotech Co., Ltd. | Method for treating coronavirus infections |
| DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| AU2021244559A1 (en) * | 2020-03-24 | 2022-11-17 | Generation Bio Co. | Non-viral DNA vectors and uses thereof for expressing Gaucher therapeutics |
| CN116234917A (zh) | 2020-07-27 | 2023-06-06 | 安杰瑞姆生物科学公司 | Dna分子组合物及其制备方法和使用方法 |
| WO2022153957A1 (ja) * | 2021-01-12 | 2022-07-21 | Ｊｃｒファーマ株式会社 | リガンドと生理活性を有する蛋白質の融合蛋白質をコードする遺伝子が組み込まれた核酸分子 |
| US20240092885A1 (en) * | 2021-01-26 | 2024-03-21 | Kriya Therapeutics, Inc. | Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same |
| CN117881786A (zh) * | 2021-04-27 | 2024-04-12 | 世代生物公司 | 表达治疗性抗体的非病毒dna载体及其用途 |
| WO2022236016A1 (en) * | 2021-05-07 | 2022-11-10 | Generation Bio Co. | Lyophilized non-viral dna vector compositions and uses thereof |
| WO2023091708A1 (en) * | 2021-11-18 | 2023-05-25 | The Brigham And Women's Hospital, Inc. | Induced proteinopathy models |
| CN118186005A (zh) * | 2022-12-12 | 2024-06-14 | 苏州荷光科汇生物科技有限公司 | 一种适于阿达木单抗的表达盒及其载体与应用 |
| US11993783B1 (en) * | 2023-03-27 | 2024-05-28 | Genecraft Inc. | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof |
| CN116549632B (zh) * | 2023-03-28 | 2024-09-10 | 中国人民解放军军事科学院军事医学研究院 | 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物 |
| WO2024234869A1 (en) * | 2023-05-15 | 2024-11-21 | Immunecare Biopharmaceuticals (Shanghai) Co., Ltd. | Recombinant fusion protein for treatment of pulmonary hypertension |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ522840A (en) * | 2000-06-01 | 2004-12-24 | Univ North Carolina | A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together |
| KR100968664B1 (ko) * | 2001-08-27 | 2010-07-06 | 제넨테크, 인크. | 항체 발현 및 조립을 위한 시스템 |
| GB0903207D0 (en) * | 2009-02-25 | 2009-04-08 | Ucb Pharma Sa | Method for expressing multimeric proteins |
| US8865881B2 (en) * | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| US9447433B2 (en) * | 2013-03-15 | 2016-09-20 | The University Of North Carolina At Chapel Hill | Synthetic adeno-associated virus inverted terminal repeats |
| TWI687225B (zh) * | 2014-02-06 | 2020-03-11 | 美商健臻公司 | 用於治療及預防黃斑部病變的組成物及方法 |
| WO2015191508A1 (en) * | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| WO2017152149A1 (en) * | 2016-03-03 | 2017-09-08 | University Of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
| US11549125B2 (en) * | 2017-08-09 | 2023-01-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof |
| AU2018330208B2 (en) * | 2017-09-08 | 2025-04-17 | Generation Bio Co. | Lipid nanoparticle formulations of non-viral, capsid-free DNA vectors |
| JP2020532981A (ja) * | 2017-09-08 | 2020-11-19 | ジェネレーション バイオ カンパニー | 修飾型閉端ｄｎａ（ｃｅｄｎａ） |
| BR112020007405A2 (pt) * | 2017-10-18 | 2020-12-08 | Regenxbio Inc. | Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos |
| KR20200093635A (ko) * | 2017-12-06 | 2020-08-05 | 제너레이션 바이오 컴퍼니 | 변형된 폐쇄된 말단 dna (cedna)를 사용한 유전자 편집 |
| SG11202005271TA (en) * | 2018-01-19 | 2020-07-29 | Generation Bio Co | Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors |
| US20210054405A1 (en) * | 2018-03-02 | 2021-02-25 | Generation Bio Co. | Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes |
-
2019
- 2019-02-14 MA MA051842A patent/MA51842A/fr unknown
- 2019-02-14 WO PCT/US2019/018016 patent/WO2019161059A1/en not_active Ceased
- 2019-02-14 SG SG11202006431WA patent/SG11202006431WA/en unknown
- 2019-02-14 JP JP2020543344A patent/JP2021513355A/ja active Pending
- 2019-02-14 CA CA3091250A patent/CA3091250A1/en active Pending
- 2019-02-14 EP EP19753655.0A patent/EP3752191A4/en active Pending
- 2019-02-14 CN CN201980013028.XA patent/CN111818942A/zh active Pending
- 2019-02-14 KR KR1020207024274A patent/KR20200120649A/ko not_active Ceased
- 2019-02-14 US US16/968,990 patent/US20220042035A1/en not_active Abandoned
- 2019-02-14 BR BR112020016288-4A patent/BR112020016288A2/pt unknown
- 2019-02-14 AU AU2019221642A patent/AU2019221642A1/en not_active Abandoned
- 2019-02-14 MX MX2020008470A patent/MX2020008470A/es unknown
-
2020
- 2020-07-03 PH PH12020551039A patent/PH12020551039A1/en unknown
- 2020-08-03 IL IL276469A patent/IL276469A/en unknown
-
2024
- 2024-08-23 JP JP2024141968A patent/JP2024167281A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513355A5 (https=) | ||
| JPWO2019161059A5 (https=) | ||
| US20210324343A1 (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step | |
| AU2018291023B2 (en) | AAV vector column purification methods | |
| JP2021513999A5 (https=) | ||
| JP2022033855A5 (https=) | ||
| CA2379564C (en) | Structural protein of adeno-associated virus with modified chromatographic properties, its production and use | |
| JP2018526003A (ja) | イヌの癌を治療するためのキメラａａｖ−抗ｖｅｇｆ | |
| JP2008506389A (ja) | Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法 | |
| RU2014146159A (ru) | Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav | |
| Demircan et al. | T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8 | |
| JP2017506230A5 (https=) | ||
| CA3129506A1 (en) | Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers | |
| RU2016135771A (ru) | Композиции и способы лечения и предотвращения дегенерации желтого пятна | |
| JPWO2019165050A5 (https=) | ||
| AR123948A1 (es) | ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES | |
| JP2021511020A5 (https=) | ||
| JPWO2020168222A5 (https=) | ||
| JPWO2020159970A5 (https=) | ||
| JPWO2020186207A5 (https=) | ||
| Youjin et al. | The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy | |
| US20240050476A1 (en) | Combination of deoxyribonuclease enzyme and cell therapies for treatment of cancer | |
| McConnell et al. | Generation Of Potent And High-Yield Exosome-Associated AAV (exoAAV) Using Engineered Exosomes | |
| CA2975569C (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step | |
| AU2024290842A1 (en) | Engineered aav capsid proteins |